

Reference:	FOI.13354.23
Subject:	Asthma treatments
Date of Request:	8 December 2023

Requested:

- How many patients have been treated (for any condition) in the last 4 months with:
 - Benralizumab
 - Dupilumab
 - Omalizumab
 - Reslizumab
 - Mepolizumab
 - Tezepelumab
- Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age groups:
 - Age 6 - 11
 - Age 12 - 17
 - Age 18 and above
- How many patients have been treated in the last 4 months by the Respiratory Medicines Department ONLY with:
 - Dupilumab
 - Omalizumab

Response:

- Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients treated with the listed medications for any condition, during the period 1 August to 30 November 2023.

Medication	Number
Benralizumab	70
Dupilumab	74
Omalizumab	17
Reslizumab	0
Mepolizumab	29
Tezepelumab	27

- The UHB is unable to provide you with the number of patients aged 6 to eleven that received Dupilumab medication, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

Additionally, all of the other patients identified in question 1, that received the listed medications were aged 18 years or over and none were aged 12 – 17.

3. The UHB provides, within the table below, the number of patients that were treated by the Respiratory Department with the listed medications, during the period 1 August to 30 November 2023.

Medication	Number
Dupilumab	6
Omalizumab	0